GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165126 | Esophagus | HGIN | maintenance of location in cell | 53/2587 | 214/18723 | 1.22e-05 | 3.45e-04 | 53 |
GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
GO:000170118 | Esophagus | HGIN | in utero embryonic development | 77/2587 | 367/18723 | 9.56e-05 | 2.05e-03 | 77 |
GO:007084918 | Esophagus | HGIN | response to epidermal growth factor | 16/2587 | 49/18723 | 6.14e-04 | 8.56e-03 | 16 |
GO:007136418 | Esophagus | HGIN | cellular response to epidermal growth factor stimulus | 15/2587 | 45/18723 | 7.05e-04 | 9.52e-03 | 15 |
GO:003812717 | Esophagus | HGIN | ERBB signaling pathway | 29/2587 | 121/18723 | 1.83e-03 | 1.97e-02 | 29 |
GO:000717317 | Esophagus | HGIN | epidermal growth factor receptor signaling pathway | 25/2587 | 108/18723 | 5.87e-03 | 4.77e-02 | 25 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
GO:003812718 | Esophagus | ESCC | ERBB signaling pathway | 82/8552 | 121/18723 | 7.23e-07 | 9.40e-06 | 82 |
GO:000717318 | Esophagus | ESCC | epidermal growth factor receptor signaling pathway | 73/8552 | 108/18723 | 3.36e-06 | 3.73e-05 | 73 |
GO:007084919 | Esophagus | ESCC | response to epidermal growth factor | 38/8552 | 49/18723 | 5.24e-06 | 5.49e-05 | 38 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:007136419 | Esophagus | ESCC | cellular response to epidermal growth factor stimulus | 35/8552 | 45/18723 | 1.11e-05 | 1.04e-04 | 35 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:00507775 | Esophagus | ESCC | negative regulation of immune response | 112/8552 | 194/18723 | 4.67e-04 | 2.62e-03 | 112 |
GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa0401219 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0523511 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0465914 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0465812 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa05110112 | Esophagus | ESCC | Vibrio cholerae infection | 34/4205 | 50/8465 | 6.62e-03 | 1.62e-02 | 8.30e-03 | 34 |
hsa0523114 | Esophagus | ESCC | Choline metabolism in cancer | 61/4205 | 98/8465 | 7.97e-03 | 1.92e-02 | 9.84e-03 | 61 |
hsa0466013 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa0501222 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0513542 | Liver | HCC | Yersinia infection | 92/4020 | 137/8465 | 2.25e-06 | 2.19e-05 | 1.22e-05 | 92 |
hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa051202 | Liver | HCC | Epithelial cell signaling in Helicobacter pylori infection | 50/4020 | 70/8465 | 3.96e-05 | 2.16e-04 | 1.20e-04 | 50 |
hsa0406622 | Liver | HCC | HIF-1 signaling pathway | 70/4020 | 109/8465 | 2.96e-04 | 1.36e-03 | 7.57e-04 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCG1 | SNV | Missense_Mutation | rs761490511 | c.1324N>A | p.Val442Met | p.V442M | P19174 | protein_coding | deleterious(0.02) | possibly_damaging(0.904) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLCG1 | SNV | Missense_Mutation | rs200504048 | c.2708C>T | p.Ser903Leu | p.S903L | P19174 | protein_coding | tolerated(0.12) | benign(0.02) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLCG1 | SNV | Missense_Mutation | novel | c.1696G>A | p.Glu566Lys | p.E566K | P19174 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PLCG1 | SNV | Missense_Mutation | novel | c.653N>A | p.Arg218His | p.R218H | P19174 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCG1 | SNV | Missense_Mutation | | c.2774A>G | p.Lys925Arg | p.K925R | P19174 | protein_coding | tolerated(0.25) | possibly_damaging(0.601) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PLCG1 | SNV | Missense_Mutation | | c.3358N>A | p.Glu1120Lys | p.E1120K | P19174 | protein_coding | deleterious(0.02) | benign(0.201) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PLCG1 | SNV | Missense_Mutation | rs565097087 | c.3758N>A | p.Arg1253His | p.R1253H | P19174 | protein_coding | tolerated(0.08) | possibly_damaging(0.563) | TCGA-BH-A0EI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCG1 | SNV | Missense_Mutation | | c.1437N>T | p.Met479Ile | p.M479I | P19174 | protein_coding | tolerated(0.38) | benign(0) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PLCG1 | SNV | Missense_Mutation | | c.2648T>A | p.Ile883Asn | p.I883N | P19174 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-E2-A1II-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PLCG1 | insertion | Frame_Shift_Ins | novel | c.3165_3166insGCAAATCTCCATGCCAAATCTCTAC | p.Thr1056AlafsTer25 | p.T1056Afs*25 | P19174 | protein_coding | | | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | propionic acid derivatives | | 26398624 |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | Pyrazolones | | 26398624 |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | 9,10-PHENANTHRENEQUINONE | 9,10-PHENANTHRENEQUINONE | |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | diclofenac | DICLOFENAC | 26398624 |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER | PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER | |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | CEFIXIME | CEFIXIME | |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | acetaminophen | ACETAMINOPHEN | 26398624 |
5335 | PLCG1 | ENZYME, KINASE, PHOSPHOLIPASE, DRUGGABLE GENOME | | aspirin | ASPIRIN | 26398624 |